PURPOSE: Numerous biologic drugs will soon be facing biosimilar competition. We study the case of trastuzumab, a revolutionary drug approved in 1998 to treat human epidermal growth factor receptor 2–positive breast cancer, to understand how trends in the price and treatment cost of the originator brand and biosimilar forms of trastuzumab evolved following biosimilar entry. METHODS: We use average…
This review critically analyzes the incidence of trastuzumab-induced left ventricular systolic dysfunction and congestive heart failure (CHF), distinguishing between cases with and without prior anthracycline…
PURPOSE Several allelic variants of the gene DPYD encoding dihydropyrimidine dehydrogenase (DPD) are associated with impaired metabolism of the systemic fluoropyrimidine fluorouracil (5FU) and its…
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limit…
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limit…
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limit…
In 2024, ASCO published a guideline on vaccination of adults with cancer. 1 This companion piece addresses some of the key questions that clinicians may…
In 2024, ASCO published a guideline on vaccination of adults with cancer. 1 This companion piece addresses some of the key questions that clinicians may…
In 2024, ASCO published a guideline on vaccination of adults with cancer. 1 This companion piece addresses some of the key questions that clinicians may…
In 2024, ASCO published a guideline on vaccination of adults with cancer. 1 This companion piece addresses some of the key questions that clinicians may…
